No.1 Healthcare & Pharma Industry Magazine for Middle East & Africa
USA — Novo Nordisk’s Ozempic, a treatment for type 2 diabetes and off-label for weight loss, is no longer on the FDA’s drug shortage list after months of limited supply.…
Read More
UNITED KINGDOM — Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to “serious breaches” of the trade…
Read More
USA — Novo Nordisk has followed in the footsteps of Eli Lilly by announcing a reduction in the prices of its insulin products in the United States two weeks after…
Read More
NETHERLANDS — The European Medicines Agency (EMA) has urged doctors to prioritize the diabetes drug Ozempic, manufactured by Novo Nordisk, for patients with diabetes who may be at risk if…
Read More
DENMARK — Novo Nordisk has announced that Jeppe Christiansen will not stand for re-election as member of the Board at the AGM to be held on 23 March 2023. The…
Read More
INDIA – Danish pharma giant Novo Nordisk has celebrated its 100th global anniversary with a special event in Bangalore, India. The major milestone comes at a point in time when…
Read More
DENMARK — Novo Nordisk’s CEO has apologized for breaching the UK industry code by not disclosing its sponsorship of obesity and weight management courses for healthcare professionals that also promoted…
Read More
UNITED KINGDOM —The president of the Association of the British Pharmaceutical Industry (ABPI) and UK head of Novo Nordisk, Pinder Sahota, has resigned from the role at the association after…
Read More
USA — The US Food and Drug Administration (FDA) has approved a label update for Novo Nordisk’s oral semaglutide (Rybelsus) allowing the agent to be used as an initial treatment…
Read More
DENMARK —Novo Nordisk has expanded its collaboration with Amalgam Rx, a US-based company to support the commercialization of Dose Check, a digital insulin initiation and titration app. Dose Check digital…
Read More